Table 2 Short-term Results: Primary and Secondary Outcomes
From: Mobile health, exercise and metabolic risk: a randomized controlled trial
Intervention (n = 67) | Active Control (n = 60) | Difference in Mean Change at 12-weeks* | ||||
|---|---|---|---|---|---|---|
Outcome measure | Baseline Mean (SD) | 12-weeks Mean (SD) | Baseline Mean (SD) | 12-weeks Mean (SD) | Estimate (95% CI) | p |
SBPrest, mmHg† | 141.2 (19.7) | 138.2 (17.8) | 141.4 (18.2) | 132.7 (18.4) | -5.68 (-10.86 to -0.50) | 0.03 |
DBPrest, mmHg† | 86.5 (11.0) | 84.0 (10.7) | 85.8 (9.3) | 80.9 (9.0) | -2.55 (-5.24 to 0.13) | 0.06 |
WC, cm | 105.5 (12.8) | 103.3 (12.3) | 102.3 (16.6) | 100.0 (16.4) | -0.36 (-2.18 to 1.46) | 0.69 |
FG, mmol/L | 5.29 (1.11) | 5.33 (1.03) | 4.87 (0.50) | 4.94 (0.51) | -0.06 (-0.24 to 0.11) | 0.47 |
HbA1c, % | 5.86 (0.75) | 5.80 (0.68) | 5.77 (0.33) | 5.75 (0.36) | 0.02 (-0.07 to 0.10) | 0.65 |
HbA1c, (mmol/mol) | 41 (8.2) | 40 (7.4) | 40 (3.6) | 39 (3.9) | 0.2 (-0.8 to 1.1) | 0.65 |
HOMA-IR‡ | 2.56 (1.88) | 2.38 (1.59) | 1.69 (1.15) | 1.92 (1.44) | 0.12 (-0.30 to 0.53) | 0.58 |
HDL, mmol/L | 1.40 (0.39) | 1.39 (0.40) | 1.45 (0.38) | 1.47 (0.38) | 0.04 (-0.03 to 0.10) | 0.26 |
LDL, mmol/L | 3.14 (0.84) | 3.09 (0.96) | 3.24 (0.78) | 3.09 (0.87) | -0.08 (-0.31 to 0.15) | 0.51 |
T-Chol, mmol/L | 5.31 (1.01) | 5.19 (1.09) | 5.37 (0.94) | 5.20 (0.98) | -0.05 (-0.30 to 0.21) | 0.72 |
TG, mmol/L | 1.68 (1.45) | 1.52 (0.87) | 1.50 (0.70) | 1.39 (0.66) | -0.04 (-0.20 to 0.13) | 0.67 |
CRPhs, mg/L | 3.46 (4.59) | 3.34 (3.61) | 2.46 (2.64) | 2.41 (3.42) | -0.16 (-0.84 to 0.53) | 0.65 |